The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global influenza diagnostics market size reached US$ 828.8 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 1,237.54 Million by 2027, exhibiting a growth rate (CAGR) of 6.70% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Influenza, or flu, refers to a viral infection that mainly affects the human respiratory system, including the nose, throat, and lungs. Influenza diagnostics includes numerous immunoassay tests that aid in detecting the presence of influenza A and B viral nucleoprotein antigens in respiratory specimens. Some of the commonly available diagnostic tests include rapid antigen testing, reverse transcription polymerase chain reaction (RT-PCR), immunofluorescence assays, serology, and rapid molecular assays. Healthcare facilities can assess the precision of these tests by looking at their sensitivity and specificity, which are crucial factors that determine their accuracy levels.
The elevating prevalence of several chronic diseases, such as asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, cystic fibrosis, etc., that increase the risk of influenza, is primarily driving the global influenza diagnostics market. Besides this, the expanding geriatric population, who are more prone to respiratory tract infections, is also catalyzing the market growth. Additionally, the rising availability of advanced diagnostic immunoassay formats along with the growing usage of miniaturized devices in influenza diagnostics is positively influencing the global market. Moreover, the introduction of CLIA-waived POC molecular influenza tests and the shifting consumer preferences from centralized laboratories to decentralized point-of-care testing are also augmenting the market growth. In addition to this, the emerging popularity of rapid influenza diagnostic test (RIDT) that are convenient to use and provide results in approximately fifteen minutes is acting as a significant growth-inducing factor. Furthermore, various initiatives by WHO to strengthen influenza surveillance, monitoring, and data utilization, are also stimulating the market growth. In line with this, numerous government bodies are becoming more actively involved in taking preventative steps to reduce the risk of influenza. For instance, the U.S. CDC and the South-East Asian Region (SEAR) have collaborated to support non-researched bilateral influenza as a response to avian, seasonal, and pandemic influenza. In the coming years, the growing integration of artificial intelligence (AI) in influenza diagnostics to minimize the timelines for sample processing and facilitate error-free results is expected to drive the global influenza diagnostics market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global influenza diagnostics market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, test type, type of flu and end user.
Breakup by Product:
Breakup by Test Type:
Breakup by Type of Flu:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton Dickinson and Company, Coris Bioconcept, Danaher Corporation, DiaSorin S.p.A., F. Hoffmann-La Roche Ltd (Roche Holding AG), Hologic Inc., Meridian Bioscience Inc., Qiagen N.V, Quidel Corporation, Sekisui Diagnostics LLC (Sekisui Medical Co. Ltd.) and Siemens Healthineers AG (Siemens AG).
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Test Type, Type of Flu, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, Becton Dickinson and Company, Coris Bioconcept, Danaher Corporation, DiaSorin S.p.A., F. Hoffmann-La Roche Ltd (Roche Holding AG), Hologic Inc., Meridian Bioscience Inc., Qiagen N.V, Quidel Corporation, Sekisui Diagnostics LLC (Sekisui Medical Co. Ltd.) and Siemens Healthineers AG (Siemens AG).|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at